Chronic plantar fasciitis remains one of the more vexing conditions in musculoskeletal medicine. While first-line conservative approaches — stretching, orthotic support, physical therapy, corticosteroid injection — resolve symptoms in approximately 80 to 85 percent of cases, a substantial minority of patients progress to refractory disease. For this population, treatment options have historically narrowed to a binary choice between ongoing symptom management and surgical fasciotomy.
Table of Contents
Over the past decade, however, transcatheter arterial embolization has emerged as a viable intermediate intervention for chronic plantar fasciitis. Originally developed for oncologic and hemorrhagic applications, embolization is now being applied to chronic musculoskeletal pain conditions — with growing clinical evidence supporting its efficacy in plantar fasciitis specifically.
The Neovascularization Hypothesis
The rationale for embolization in chronic plantar fasciitis rests on a well-documented histopathological observation: persistent plantar fasciitis is associated with neovascularization of the affected tissue.
In the acute phase of plantar fasciitis, inflammation triggers angiogenesis as part of the normal repair response. In most patients, this resolves as the fascia heals. But in a subset of chronic cases, the angiogenic process becomes dysregulated. Clusters of abnormal microvessels proliferate around the injured fascia — vessels that do not contribute to tissue repair but instead sustain a chronic inflammatory microenvironment.
Critically, these neovascular formations are accompanied by neoinnervation: new sensory nerve fibers that grow alongside the aberrant vasculature. The combination of ongoing inflammatory cell delivery through the new blood supply and amplified nociceptive signaling through the new nerve fibers creates a self-perpetuating pain cycle that is resistant to conventional anti-inflammatory approaches.
This is the biological basis for why corticosteroid injections often provide only transient relief in chronic cases of plantar fasciitis. The injection suppresses inflammation temporarily, but the vascular substrate remains intact. Once the pharmacologic effect dissipates, the inflammatory cascade resumes.
Embolization Technique and Mechanism
Plantar fasciitis embolization (PFE) applies the principle of targeted vascular occlusion to this problem. The technique was adapted from transarterial micro-embolization (TAME), developed by Dr. Yuji Okuno and colleagues in Japan, initially for chronic musculoskeletal pain conditions including adhesive capsulitis and lateral epicondylitis.
The procedure is performed under local anesthesia via a percutaneous approach, typically through the dorsalis pedis or posterior tibial artery at the ankle. A microcatheter is advanced under fluoroscopic guidance to the arterial branches supplying the neovascular clusters around the plantar fascia. Calibrated microspheres — typically in the 75 to 150 micron range — are then delivered to selectively occlude these abnormal feeding vessels while preserving normal arterial flow to the foot.
The targeted nature of the intervention is a key differentiator. Unlike corticosteroid injection, which provides systemic anti-inflammatory effects within a localized area, embolization addresses the structural vascular pathology itself. By eliminating the abnormal blood supply, the procedure disrupts both the inflammatory cell delivery and the neoinnervation that sustain chronic pain.
Published Clinical Outcomes
The evidence base for PFE, while still maturing, is substantive enough to merit serious clinical consideration.
Okuno et al. (2017, 2019): The largest published series to date includes 66 patients with chronic plantar fasciitis (mean symptom duration exceeding 12 months) who underwent transcatheter arterial embolization. At three-month follow-up, 85 percent of patients demonstrated clinically significant pain reduction as measured by visual analog scale (VAS) scores. At 12 months, improvement was sustained in the majority of responders, with mean VAS scores decreasing from approximately 7.5 to 2.0.
Subsequent case series from both Japanese and Western centers have reported concordant results, with response rates consistently in the 80 to 90 percent range. Adverse events have been minimal — predominantly limited to transient access-site discomfort and occasional mild skin discoloration, with no reported cases of tissue necrosis or clinically significant non-target embolization.
Comparative context: While randomized controlled trials comparing PFE directly to surgical fasciotomy are not yet available, the published efficacy rates are comparable to those reported for open and endoscopic plantar fascia release — with substantially less procedural morbidity, shorter recovery time, and no requirement for general anesthesia.
Recovery Profile and Patient Selection
The recovery characteristics of PFE align more closely with injection-based therapies than with surgical interventions:
- Immediate post-procedure: Patients ambulate independently. No immobilization or weight-bearing restrictions are imposed.
- Days 1–7: Mild access-site soreness; normal daily activities including walking are typically tolerated.
- Weeks 2–6: Progressive symptom improvement. Pain reduction is gradual rather than immediate, consistent with the time required for inflammatory resolution following vascular occlusion.
- Months 2–3: Maximal therapeutic effect is generally achieved.
Appropriate patient selection is essential for optimizing outcomes. Current clinical consensus supports PFE for patients meeting the following criteria:
- Confirmed plantar fasciitis diagnosis (clinical examination ± imaging)
- Symptom duration exceeding six months
- Inadequate response to structured conservative management including physical therapy, orthotic support, and at least one corticosteroid injection
- No contraindications to arterial catheterization (severe peripheral arterial disease, active infection)
The Expanding Role of Embolization in MSK Medicine
PFE represents one application within a broader paradigm shift in musculoskeletal pain management. The same embolization principles are being applied to genicular artery embolization (GAE) for chronic knee osteoarthritis, where abnormal neovascularization of the synovium and periarticular tissues plays an analogous pathophysiologic role. GAE has progressed further in the evidence base, with multi-center trials now underway, and is increasingly recognized as a viable option for knee pain patients who wish to delay or avoid arthroplasty.
The conceptual through-line is consistent: in conditions where chronic pain is maintained by aberrant neovascularization and associated neoinnervation, targeted embolization of the feeding vessels can interrupt the pain cycle without the tissue destruction inherent to surgical approaches.
Practitioners like Dr. David Fox at Fox Vein & Vascular in Manhattan are integrating both PFE and GAE into collaborative care models, working alongside referring podiatrists, orthopedic surgeons, and pain management specialists to identify appropriate candidates and optimize outcomes through multidisciplinary coordination.
Looking Forward
The trajectory of embolization in musculoskeletal medicine parallels the early adoption curve of many interventional techniques that have since become standard of care. The biological rationale is sound, the procedural safety profile is favorable, and the clinical outcomes — while requiring validation through larger randomized trials — are consistently encouraging across published series.
For clinicians managing patients with refractory plantar fasciitis, transcatheter embolization warrants consideration as a well-supported intermediate intervention between failed conservative care and surgical fasciotomy.
This article was written for WHN by Parker, who is a health and wellness content writer with a strong interest in evidence-based healthcare, longevity, preventive medicine, and emerging medical technologies. Their work focuses on creating accurate, informative content that helps readers better understand health innovations, patient care, and strategies for long-term well-being.
As with anything you read on the internet, this article on plantar fasciitis should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. WHN neither agrees nor disagrees with any of the materials posted. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement.
Opinion Disclaimer: The views and opinions expressed in this article on plantar fasciitis are those of the author and do not necessarily reflect the official policy of WHN. Any content provided by guest authors is of their own opinion and is not intended to malign any religion, ethnic group, club, organization, company, individual, or anyone or anything else. The Food and Drug Administration has not evaluated these statements.
